← Research library

Clinical pharmacokinetics of Kemantane in bronchial disease

Study involving people · 1991

What was studied
Patients with bronchial disease. Enrollment was not stated in the abstract.
Main finding
Gas–liquid chromatography detected little parent compound in blood. The authors attributed this to first-pass metabolism and characterized exposure using the principal active metabolite.

Reported findings and study design

Findings described in words

Gas–liquid chromatography in patients with bronchial disease.

Population or model Patients with bronchial disease. Enrollment was not stated in the abstract.

Results · Indexed English abstract of the original Russian journal report.
MeasureResultComparison, timing and statistics
Parent compound in bloodLittle or no detectable parent Kemantane. The authors evaluated exposure through its major active metabolite.

The abstract provides no numerical estimates, dose, sampling schedule or group sizes.

Source for these results ↗ · Reviewed 2026-11-14

Study limitations and source details

Study limitations

  • The abstract does not provide the dose, sampling schedule or numerical pharmacokinetic estimates. This report assesses exposure.

Source details

Indexed English abstract of the original Russian journal report.

Sources checked

Citation

Human study · design details unresolvedEnglish abstract

S. S. Boiko, V. P. Zherdev, N. A. Kisliak. Clinical pharmacokinetics of Kemantane in bronchial disease Farmakol Toksikol. 1991;54(1):57–59.

Study source ↗ · Bibliography entry · Link to this summary

Related compounds

Editorial policy and evidence standards